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Abstract
Purpose: The present study aimed at evaluating the efficacy of Raltitrexed, a specific thymidilate
synthase inhibitor, in patients with advanced colorectal cancer (ACC) in relapse (>8 weeks) after
a prior response or disease stabilization to first-line chemotherapy combination with lrinotecan+5-
Fluorouracil (5-FU)+Leucovorin (LV).
Methods: Twenty-five patients with metastatic ACC entered; 17 males/8 females, median age 61
(range: 47–70), median Karnovsky PS: 80 (70–90), and sites of metastases; liver: 21, lung: 4, lymph
nodes: 7, peritoneal: 5 and a life expectancy of at least 3 months, were entered in the present pilot
study. All patients had progressed after prior chemotherapy with lrinotecan+5-FU+LV. Raltitrexed
was administered at a dose of 3 mg/m2 i.v. every 21 days.
Results: Three patients (12%) achieved a partial response (PR), 8 (32%) had stable disease (SD),
and the remaining 14 (56%) developed progressive disease (PD). Median time-to-progression (TTP)
was 5.5 months (range, 2–8.5), and median overall survival (OS) 8 months (range, 4.0–12.5).
Toxicity was generally mild; it consisted mainly of myelosuppression; neutropenia grade 1–2: 52%-
grade 3: 28%, and anemia grade 1–2 only: 36%. Mild mucositis grade 1–2 occured in 13.5% of
patients and was the principal non-hematologic toxicity.
Conclusion: Response to treatment with Raltitrexed is limited in patients with ACC failing after
an initial response or non-progression to the weekly lrinotecan+5-FU+LV combination. However,
it appears that a limited number of patients with PR/SD may derive clinical benefit, but final proof
would require a randomized study.
Background
Treatment of advanced colorectal cancer has been mini-
mally successful due to the poor response of the disease to
classic cytotoxic agents. Antimetabolites, such as MTX and
5-FU, have been in clinical use for many years. Both
agents exert their cytotoxic action by inhibiting thymidi-
late synthase (TS) the rate-limiting enzyme that methyl-
ates deoxyuridine monophosphate (dUMP) to thymidine
monophosphate (TMP); the reaction requires reduced
folate as a cofactor and leads to incorporation of thymi-
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dine triphosphate into the DNA [1]. 5-FU is converted in-
tracellularly to 5-FdUMP, which inhibits TS. Folinic acid
(leucovorin) potentiates this inhibitory effect on TS by
forming a ternary complex with the enzyme. Moreover, 5-
FdUMP inhibits purine synthesis and exerts inhibitory ef-
fects not only on DNA but on RNA, as well. These non-
specific non-TS dependent effects on RNA are believed to
account at a certain degree for the toxicity encountered
with 5-FU, such as mucositis [1].
Raltitrexed (Tomudex) represents a specific TS inhibitor
not requiring modulation and not having any non-specif-
ic effects on RNA. Phase II studies with Raltitrexed at 3
mg/m2 iv every 21 days demonstrated activity in a variety
of advanced solid tumors, and most notably in advanced
colorectal cancer and breast cancer [2]. Moreover, a subse-
quent randomized trial comparing Raltitrexed versus 5-
FU+LV in chemotherapy-naive patients with advanced
colorectal cancer, demonstrated equal activity and surviv-
al figures with reduced toxicity, regarding mucositis and
leukopenia, for Raltitrexed [3]. Response rates with Ralti-
trexed have been in the range of 20–30% in patients with
advanced colorectal cancer [2,3].
Irinotecan represents an active agent in advanced colorec-
tal cancer relapsing after 5-FU+LV based combination as
demonstrated in two recent large multi-institutional con-
trolled phase III studies [4,5]. However, despite the clini-
cal benefit derived from CPT-11 treatment in relapsed
ACC, patients generally develop PD quite rapidly and
might be candidates for further experimental treatment.
Sometimes long response durations are observed. Further-
more, as demonstrated in two recent randomized trials by
Douillard et al[6] and Saltz et al[7], combination chemo-
therapy with 5-FU, LV and Irinotecan provided improved
response rates and survival advantage over both bolus 5-
FU and continuous infusion 5-FU modulated with LV
without compromising quality of life [7]. These results are
very encouraging and suggest that the addition of Irinote-
can to LV+5-FU has an important role in the front-line
treatment of patients with ACC.
It is currently unknown whether treatment with Ralti-
trexed after prior lrinotecan+5-FU+LV would have any
clinical effect, since both Raltitrexed and 5-FU target the
same enzyme (TS) and it is therefore anticipated that a
high level of cross-resistance might exist. Moreover, lri-
notecan+5-FU+LV is currently the most active first-line
and it is not yet known whether other second-line drugs
might be active in this setting.
Patients and Methods
Patients
Twenty-five patients with reccurent or metastatic adeno-
carcinoma of the colon and rectum, that had been treated
at first-line with lrinotecan+5-FU+LV and relapsed at least
8 weeks after last treatment entered this study (Table 1).
Eligibility criteria
Eligibility criteria included bi-dimensionally measurable
disease, performance status (PS) (Karnofsky) equal or
>70, life expectancy of at least 3 months. Patients had to
have normal hematologic, renal or hepatic function tests
unless the abnormalities had resulted from direct tumor
invasion. Moreover, absence of brain metastases, active
ischemic cardiac disease or cardiac insufficiency, absence
of psychotic disorders, diabetes and cirrhosis was re-
quired. A histological documentation of measurable met-
astatic disease was obtained whenever possible. All
patients had previously undergone chemotherapy with
the weekly Irinotecan (60 mg/m2)+5-FU (400 mg/
m2)+LV (200 mg/m2) regimen (with no planned breaks
unless the occurrence of grade III toxicity or PD) and had
achieved a CR/PR or SD and progressed at least 8 weeks
off treatment. Informed consent was obtained from all pa-
tients according to Institutional policies.
Treatment
Treatment was carried-out in the day clinic. Raltitrexed
was administered at a dose of 3 mg/m2 i.v. infusion for 30
min, every 21 days. Treatment was continued for 2 cycles
beyond maximal response (CR/PR) or until tumor pro-
gression. In the event of >grade II myelosupppression on
the day of treatment, or other non-hematologic toxicities
according to WHO [8], treatment was delayed until recov-
ery, or for a maximum of 2 weeks, after which no further
treatment was administered in the case that blood counts
had not returned to normal (neutrophils > 1500 /µL and
platelets > 100.000/µL). The dose of Raltitrexed was kept
stable, if no toxicity ≥  grade 3 was encountered. In the case
of ≥  grade 3 hematologic or non-hematologic (except alo-
pecia, nausea and vomiting) toxicity subsequent doses of
Table 1: Patients' characteristics
Number 25
Sex
Men 17
Women 8
Median Age 61 (range, 47–70)
Median PS (Karnovsky) 80 (range, 70–90)
Primary
Colon 21
Rectum 4
Metastases
Liver 21
Lung 4
Lymph nodes 7
Peritoneal 5BMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/2
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Raltitrexed were reduced by 20%, and beyond a 40% max-
imum dose reduction no further treatment was adminis-
tered.
Criteria for response and follow-up
Before each treatment cycle every patient had a complete
blood count, serum biochemistry, ECG, chest roentgenog-
raphy, and abdominal CT scan. Between the treatment cy-
cles CBC's were performed weekly. Patients were
evaluated for response every two cycles of treatment. A
complete response (CR) was defined as a complete dissap-
pearance of all clinically evident disease. Partial response
(PR) was defined as a decrease of than 50% in the sum of
the products of the largest perpedicular diameters of the
measurable lesions. Both CR and PR had to have a mini-
mum duration of 4 weeks. A <50% reduction up to 25%
increase in the sum of the products of the largest perpen-
dicular diameters of all measurable lesions defined as Sta-
ble Diasease (SD). For all response definitions a
minimum 4-week duration was required for qualifying for
each type of response (CR, PR, SD). Progressive Disease
(PD) was an increase of the above measurements or the
appearance of new lesions. Clinical benefit was defined as
improvement of disease-related symptoms, an increase in
Karnovsky PS by >15, and the absence of major cumula-
tive toxicity, such as fatigue or weight loss related to treat-
ment.
After the end of treatment, patients were followed with
clinical examination, blood counts, serum biochemistry
and serum tumor marker levels (CEA, CA-19.9), CT scans
of the chest and abdomen or any other indicated sites eve-
ry 3 months.
Toxicity
Toxicity was estimated according to WHO criteria [8]. We
also evaluated the highest grade of toxicity for each pa-
tient during the treatment course, in order to find during
which time period of therapy we would expect the highest
grade of toxicity.
Statistical methods
Time to progression was calculated from the day of study
entry until evidence of progressive disease; overall survival
was measured from the day of entry to the study until last
folow-up or death. The 95% confidence intervals (Cl) for
response rates were calculated from the binomial distribu-
tion. For a new drug in the setting of relapsed ACC, a 15%
response rate (RR; CR+PR) was anticipated as satisfactory
to proceed to further phase II patient accrual. With a max-
imum of 7% standard error (SE) for RR, the minimum
sample size required to satisfy these conditions was 25 pa-
tients. If less than 4 responses were recorded among the
initial 25 patients the drug would be considered inactive
(with a power >90%, at a 0.05 significance) and the study
would be stopped.
Results
Twenty-five patients entered the study between September
1999 and October 2000 and all were evaluable for toxicity
and response. Three patients experienced achieved PR, 8
(32%) had SD, and the remaining 14 (56%) developed
PD. All three patients with PR had a prior response (1 CR
and 2 PRs) to first-line weekly lrinotecan+5-FU+LV. More-
over, 7/8 patients with SD to second-line Raltitrexed had
experienced a PR to prior first-line lrinotecan+5-FU+LV.
Indeed all 3 patients with a PR and 5/8 with SD to Ralti-
trexed had improvement in disease-related symptoms
(overall 8/25 patients; 32%), while 2 of these patients had
improvement of PS from 70 to 90, in addition, and were
therefore considered as having derived clinical benefit ac-
cording to our definitions (see also Patients & Methods).
In view of the lower than the pre-determined RR (see Sta-
tistical Methods) for further patient accrual, we decided to
terminate the study at this stage.
Median TTP was 5.5 mo (range, 2–8.5), and median OS 8
mo (range, 4.0–12.5). The median duration of previous
treatment with lrinotecan+5-FU+LV first-line chemother-
apy was 5 mo (range, 4–8), corresponding to 5 treatment
cycles (range, 4–8) (1 treatment cycle with lrinotecan+5-
FU+LV = 1 mo; 4 weeks). After a median time of 4.5 mo
(range, 2–14) off treatment all patients started second-
line chemotherapy with Raltitrexed for a median duration
of treatment of 3 mo (range 1-7). The median number of
Raltitrexed cycles was 4 (range, 2–8). For the three pa-
tients achieving PR, TTPs were 3.5, 6.5 and 8.5 mo, while
survivals were 6, 8.5, and 12.5 mo, respectively.
Toxicity was evaluated according to WHO grading and
consisted principaly of myelotoxicity; neutropenia (Grade
1–2, 54/104 cycles: 52%; Grade 3, 29/104 cycles: 28%),
anemia (decrease of Hgb> 3 gr/dl) grade 1–2 only (37/
104 cycles; 36%), and diarrhea Grade 1–2, 32/104 cycles:
31%, Grade 3, 26/104 cycles: 25%. Other toxicity param-
eters include nausea-vomiting (Grade 1–2, 33/104 cycles;
32%), mucositis (Grade 1–2, 14/104 cycles; 13.5%), fa-
tigue (11/25 patients; 44%), worsening PS (6/25 patients;
24%), transaminase increase (3/25 patients, 12%).
Discussion
The present study demonstrated that the activity of Ralti-
trexed when used as salvage treatment in ACC after re-
lapse/progression with first-line weekly lrinotecan+5-
FU+LV is rather limited. However, a not negligible pro-
portion of patients (32%) derives clinical benefit. It
should be noted that all these 3 patients achieving PR and
7/8 with SD to Raltitrexed, i.e. overall 40% of patients,
had responded to prior lrinotecan+5-FU+LV.BMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/2
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The experience was different when Raltitrexed has been
applied as a first-line agent. Three large multi-institutional
randomized clinical trials demonstrated that the objective
RR (CR+PR) with Raltitrexed ranged from 14% to 19%,
and was similar to that of 5-FU modulated by either low-
dose or high-dose Leucovorin [9–11]. However, in one of
the above studies [10] with a minimum follow-up time of
12 months, there was no significant difference between
the groups in RR (14% Raltitrexed vs 15% 5-FU+LV), but
median TTP and OS time were significantly longer for the
5-FU+LV group. Median survival time was 12.7 months
and 9.7 months for the 5-FU+LV and Raltitrexed groups,
respectively [10]. The number of patients with SD was also
similar for Ratitrexed and 5-FU/LV. Moreover, survival
was comparable between Raltitrexed and 5-FU+LV treated
groups in both studies. It was concluded that Raltitrexed
might be favored over either 5-FU+LV combinations, giv-
en its ease of administration (one day every 3 weeks), re-
duced visits in the outpatient department and overall
length of treatment and reduced non-hematologic toxici-
ties, such as mucositis, diarrhea and hematologic toxicity,
predominantly mild and uncomplicated neutropenia.
Despite the fact that Raltitrexed produces palliative bene-
fits for patients with advanced colorectal cancer when
used as first-line treatment, it is questionable whether it
has any significant impact when used as second or third-
line treatment in patients failing prior 5-FU+LV and CPT-
11-based regimens.
The present phase II study indicates that Raltitrexed has
limited activity in patients that have failed the most active
first-line chemotherapy regimen for ACC, incorporating
weekly lrinotecan+5-FU+LV [6,7]. The possible explana-
tions are that Raltitrexed and 5-FU have the same bio-
chemical target; thymidylate synthase, however, with
different properties of enzyme inhibition [10], or that pa-
tients with advanced stages of disease and heavily pre-
treated might have limited chances to respond or benefit
from any type of further treatment. Moreover, given that a
prerequisite for entering the present study was that, pa-
tients had to have progressed from PR or SD at least after
2 months after the end of first-line treatment, it is antici-
pated that a group of patients with rather sensitive disease
might have been selected. As the RR was only 12%, the
present study demonstrates that at relapse, after the most
active at present first-line regimen-incorporating all most
active agents-the emerging tumor cell clones are possibly
resistant to any available further alternative treatment.
However, a recent study in patients with ACC refractory to
lrinotecan/5-FU/LV reported a 21% response rate with in-
fusional Oxaliplatin/5-FU/LV (Oxaliplatin-de Gramont
regimen) [12].
Toxicity was acceptable in the present study, albeit with an
increased incidence of neutropenia, anemia, nausea and
diarrhea, most likely attributed to heavy pre-treatment
and/or more advanced disease status and functional im-
pairment. However, a high rate of unexpected toxicity has
been reported with Raltitrexed with an 18% serious ad-
verse event (SAE) rate and 4% toxic deaths compared to
3% SAE for the de Gramont regimen and 12% for the con-
tinuous low-dose 5-FU Lokich regimen, with no toxic
deaths in the latter two 5-FU regimens in a multicenter
randomized trial comparing the above three regimens
[13,14]. Based on these findings, further interest in this
agent has substantially declined.
Conclusions
The present study demonstrated that Raltitrexed when
used as second-line treatment after prior lrinotecan+5-
FU+LV in ACC has limited activity, a 12% RR, and pro-
vides clinical benefit in 32% of these patients pre-treated
with the most active first-line combination of lrinote-
Table 2: Toxicity parameters (104 cycles in 25 patients).
Parameter Grade (WHO) Per Cycle Percentage (%)
Neutropenia 1–2 54/104 52%
3–4 29/104 28%
Anemia (Hg>3 gr/dl) 1–2 37/104 36%
Diarrhea 1–2 32/104 31%
3 26/104 25%
Nausea-Vomiting 1–2 33/104 32%
Mucositis 1–2 14/104 13.5%
Per Patient
Fatigue 1–2 11/25 44%
Transaminases (ALT/AST) 1–2 3/25 12%
Worsening PS 6/25 24%BMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/2
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can+5-FU+LV. Its application in earlier phases of treat-
ment and possibly in combination with other active
agents, such as oxaliplatin in second-line might further
improve the outcome of these patients.
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